HCW Biologics Inc.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
HCWB$1.02-1.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of operations
Condensed Statements of Operations
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2025 | 2026 | 2025 | 2026 | |
| Revenues: | ||||
| Revenues | $6,550 | $135,568 | $11,615 | $6,678,569 |
| Cost of revenues | (5,240) | (229,455) | (9,292) | (240,526) |
| Gross Profit | 1,310 | (93,887) | 2,323 | 6,438,043 |
| Operating expenses: | ||||
| Research and development | 1,226,824 | 1,203,352 | 2,705,536 | 2,461,300 |
| General and administrative | 2,096,021 | 1,870,375 | 4,302,301 | 3,703,652 |
| Legal expenses (recoveries), net | 142,542 | (1,325) | (1,596,951) | 5,525 |
| Indirect tax expense | - | - | - | 198,146 |
| Total operating expenses | 3,465,387 | 3,072,402 | 5,410,886 | 6,368,623 |
| Operating income (loss) | (3,464,077) | (3,166,289) | (5,408,563) | 69,420 |
| Interest expense | (228,714) | (100,541) | (505,853) | (209,815) |
| Change in fair value of warrant liability | - | (2,443,335) | - | (1,775,992) |
| Change in fair value of investment, net | 1,748,688 | - | 1,748,688 | - |
| Gain on extinguishment of liability | - | 483,383 | - | 483,383 |
| Other income, net | 16,373 | 7,551 | 41,122 | 16,439 |
| Net loss before income taxes | (1,927,730) | (5,219,231) | (4,124,606) | (1,416,565) |
| Income tax expense | - | - | - | (330,186) |
| Net loss | $(1,927,730) | $(5,219,231) | $(4,124,606) | $(1,746,751) |
| Equity dividend to investor | (10,153,799) | (10,154,642) | (10,153,799) | (11,643,114) |
| Net loss attributable to Common Stockholders | $(12,081,529) | $(15,373,873) | $(14,278,405) | $(13,389,865) |
| Net loss per share, basic and diluted | $(40.72) | $(11.58) | $(59.14) | $(11.98) |
| Weighted average shares outstanding, basic and diluted | 296,686 | 1,327,966 | 241,417 | 1,117,350 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.